Difluprednate | CAS#23674-86-4 | corticosteroid

MedKoo Cat#: 317614 | Name: Difluprednate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Difluprednate is a corticosteroid. It is chemically a butyrate ester of 6(alpha),9(alpha)-difluoro prednisolone acetate. Accordingly, difluprednate is sometimes abbreviated DFBA, for difluoroprednisolone butyrate acetate.

Chemical Structure

Difluprednate

CAS#23674-86-4

Theoretical Analysis

MedKoo Cat#: 317614

Name: Difluprednate

CAS#: 23674-86-4

Chemical Formula: C27H34F2O7

Exact Mass: 508.2273

Molecular Weight: 508.55

Elemental Analysis: C, 63.77; H, 6.74; F, 7.47; O, 22.02

Price and Availability

Size	Price	Availability
200mg	USD 250.00	2 Weeks
500mg	USD 450.00	2 Weeks
1g	USD 750.00	2 Weeks
2g	USD 1,250.00	2 Weeks
5g	USD 2,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

W 6309; W-6309; W6309; Difluprednate; Durezol; Epitopic

IUPAC/Chemical Name

(6S,8S,10S,11S,13S,14S,17R)-17-(2-acetoxyacetyl)-6,9-difluoro-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl butyrate

InChi Key

WYQPLTPSGFELIB-KGQPDAEUSA-N

InChi Code

InChI=1S/C27H34F2O7/c1-5-6-23(34)36-26(22(33)14-35-15(2)30)10-8-17-18-12-20(28)19-11-16(31)7-9-24(19,3)27(18,29)21(32)13-25(17,26)4/h7,9,11,17-18,20-21,32H,5-6,8,10,12-14H2,1-4H3/t17-,18-,20-,21-,24-,25-,26-,27?/m0/s1

SMILES Code

C[C@@]12[C@](C(COC(C)=O)=O)(OC(CCC)=O)CC[C@@]1([H])[C@]3([H])C[C@H](F)C4=CC(C=C[C@]4(C)C3(F)[C@@H](O)C2)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 508.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Symes RJ, Forooghian F. Topical difluprednate monotherapy for uveitic macular edema. Can J Ophthalmol. 2016 Feb;51(1):47-9. doi: 10.1016/j.jcjo.2015.10.007. PubMed PMID: 26874159. 2: Kaur S, Yangzes S, Singh S, Sachdev N. Efficacy and safety of topical difluprednate in persistent diabetic macular edema. Int Ophthalmol. 2015 Aug 22. [Epub ahead of print] PubMed PMID: 26296375. 3: Onishi SM, Asahi MG, Chou C, Gallemore RP. Topical difluprednate for the treatment of Harada's disease. Clin Ophthalmol. 2015 Jan 21;9:157-67. doi: 10.2147/OPTH.S72955. eCollection 2015. PubMed PMID: 25653498; PubMed Central PMCID: PMC4310279. 4: Giacobbe C, Palmisano G, Giovenzana GB, Giovannelli L, Negri R, Masciocchi N. Difluprednate: more than meets the eye. J Pharm Biomed Anal. 2015 Jan;102:305-13. doi: 10.1016/j.jpba.2014.09.028. Epub 2014 Sep 30. PubMed PMID: 25459928. 5: Jeng KW, Fine HF, Wheatley HM, Roth D, Connors DB, Prenner JL. Incidence of steroid-induced ocular hypertension after vitreoretinal surgery with difluprednate versus prednisolone acetate. Retina. 2014 Oct;34(10):1990-6. doi: 10.1097/IAE.0000000000000215. PubMed PMID: 25121927. 6: Sheppard JD, Toyos MM, Kempen JH, Kaur P, Foster CS. Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study. Invest Ophthalmol Vis Sci. 2014 May 6;55(5):2993-3002. doi: 10.1167/iovs.13-12660. PubMed PMID: 24677110; PubMed Central PMCID: PMC4581692. 7: Yamamoto T, Nakano Goto S, Abe S, Kirii E, Yamashita H. Difluprednate ophthalmic emulsion 0.05% as adjunctive treatment to panretinal photocoagulation for proliferative diabetic retinopathy with clinically significant macular edema. Retin Cases Brief Rep. 2012 Summer;6(3):228-31. doi: 10.1097/ICB.0b013e318224776f. PubMed PMID: 25389718. 8: Slabaugh MA, Herlihy E, Ongchin S, van Gelder RN. Efficacy and potential complications of difluprednate use for pediatric uveitis. Am J Ophthalmol. 2012 May;153(5):932-8. doi: 10.1016/j.ajo.2011.10.008. Epub 2012 Jan 20. PubMed PMID: 22265149. 9: Chalam K, Khetpal V, Patel CJ. Spectral domain optical coherence tomography documented rapid resolution of pseudophakic cystoid macular edema with topical difluprednate. Clin Ophthalmol. 2012;6:155-8. doi: 10.2147/OPTH.S28151. Epub 2012 Jan 24. PubMed PMID: 22291458; PubMed Central PMCID: PMC3267537. 10: Donnenfeld ED, Holland EJ, Solomon KD, Fiore J, Gobbo A, Prince J, Sandoval HP, Shull ER, Perry HD. A multicenter randomized controlled fellow eye trial of pulse-dosed difluprednate 0.05% versus prednisolone acetate 1% in cataract surgery. Am J Ophthalmol. 2011 Oct;152(4):609-617.e1. doi: 10.1016/j.ajo.2011.03.018. Epub 2011 Jun 25. PubMed PMID: 21704965. 11: Birnbaum AD, Jiang Y, Tessler HH, Goldstein DA. Elevation of intraocular pressure in patients with uveitis treated with topical difluprednate. Arch Ophthalmol. 2011 May;129(5):667-8. doi: 10.1001/archophthalmol.2011.82. Erratum in: Arch Ophthalmol. 2011 Jul;129(7):935. PubMed PMID: 21555625. 12: Mulki L, Foster CS. Difluprednate for inflammatory eye disorders. Drugs Today (Barc). 2011 May;47(5):327-33. doi: 10.1358/dot.2011.47.5.1590791. Review. PubMed PMID: 22013563. 13: Tajika T, Waki M, Tsuzuki M, Kida T, Sakaki H. Pharmacokinetic features of difluprednate ophthalmic emulsion in rabbits as determined by glucocorticoid receptor-binding bioassay. J Ocul Pharmacol Ther. 2011 Feb;27(1):29-34. doi: 10.1089/jop.2010.0106. Epub 2010 Dec 23. PubMed PMID: 21182429. 14: Tajika T, Isowaki A, Sakaki H. Ocular distribution of difluprednate ophthalmic emulsion 0.05% in rabbits. J Ocul Pharmacol Ther. 2011 Feb;27(1):43-9. doi: 10.1089/jop.2010.0093. Epub 2010 Dec 1. PubMed PMID: 21118027. 15: Kurz PA, Chheda LV, Kurz DE. Effects of twice-daily topical difluprednate 0.05% emulsion in a child with pars planitis. Ocul Immunol Inflamm. 2011 Feb;19(1):84-5. doi: 10.3109/09273948.2010.512993. Epub 2010 Oct 31. PubMed PMID: 21034305. 16: Donnenfeld ED. Difluprednate for the prevention of ocular inflammation postsurgery: an update. Clin Ophthalmol. 2011;5:811-6. doi: 10.2147/OPTH.S6541. Epub 2011 Jun 15. PubMed PMID: 21750615; PubMed Central PMCID: PMC3130919. 17: Meehan K, Vollmer L, Sowka J. Intraocular pressure elevation from topical difluprednate use. Optometry. 2010 Dec;81(12):658-62. doi: 10.1016/j.optm.2010.09.001. PubMed PMID: 21111374. 18: Stringer W, Bryant R. Dose uniformity of topical corticosteroid preparations: difluprednate ophthalmic emulsion 0.05% versus branded and generic prednisolone acetate ophthalmic suspension 1%. Clin Ophthalmol. 2010 Oct 5;4:1119-24. doi: 10.2147/OPTH.S12441. PubMed PMID: 20957058; PubMed Central PMCID: PMC2952614. 19: Foster CS, Davanzo R, Flynn TE, McLeod K, Vogel R, Crockett RS. Durezol (Difluprednate Ophthalmic Emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis. J Ocul Pharmacol Ther. 2010 Oct;26(5):475-83. doi: 10.1089/jop.2010.0059. PubMed PMID: 20809807. 20: Smith S, Lorenz D, Peace J, McLeod K, Crockett RS, Vogel R. Difluprednate ophthalmic emulsion 0.05% (Durezol) administered two times daily for managing ocular inflammation and pain following cataract surgery. Clin Ophthalmol. 2010 Sep 7;4:983-91. PubMed PMID: 20856594; PubMed Central PMCID: PMC2938279.